acalabrutinib
2 clinical trials
2 products
12 abstracts
3 indications
1 target
Indication
Chronic Lymphocytic LeukemiaIndication
Small Lymphocytic LymphomaIndication
Prolymphocytic LeukemiaAbstract
Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA).Org: Beigene Netherlands B.V., The Alfred and Monash University,
Abstract
BELLWAVE-011: Phase 3 randomized trial of nemtabrutinib versus ibrutinib or acalabrutinib in untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom, Haematology Unit, Bnai Zion Medical Center, Haifa, Israel, Department of Hematology & BMT, Chaim Sheba Medical Center, Tel Aviv, Israel, Summit Cancer Center, Spok, WA, Hadassah Medical Center, Jerusalem, Israel,
Abstract
Risk assessment of cardiovascular adverse events with BTK inhibitors in hematological malignancies: Insights from FAERS.Org: Cincinnati Children s Hospital Medical Center,
Abstract
Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices.Org: University of Pittsburgh Medical Center (UPMC), Integra Connect PrecisionQ, BeiGene,
Clinical trial
A Phase 1b Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed / Refractory or Untreated CLL/SLL/PLLStatus: Active (not recruiting), Estimated PCD: 2021-08-20
Abstract
Risk of new-onset hypertension in patients (pts) with newly diagnosed chronic lymphocytic leukemia (CLL) treated with Bruton tyrosine kinase inhibitors (BTKi): A real-world data study using the Symphony Health Solution database.Org: Cardiology Center, Canton, CT,
Clinical trial
Acalabrutinib Real World Italian obSErvational Secondary Data Collection Study of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia.Status: Recruiting, Estimated PCD: 2030-02-28
Abstract
Association of pharmacist interventions with adherence upon targeted anticancer oral therapy initiation.Org: VA Salt Lake City Health Care, AbbVie Inc., North Chicago, IL, Hunstman Cancer Institute at the University of Utah,
Abstract
Utility of pharmacogenomic testing in predicting intolerance to BTK inhibitors.Org: Duke Cancer Institute, Durham, NC, Durham VA Medical Center, VA National Precision Oncology Program, VA National Oncology Program Office,
Abstract
Safety and efficacy of ABR in pts with TN or R/R MCL: Ph Ib trial.Org: AstraZeneca, Cambridge, United Kingdom, AstraZeneca, South San Francisco, CA,
Abstract
A study of frontline therapy in adults >80 years with chronic lymphocytic leukemia (CLL).Org: Mayo Clinic, Division of Clinical Trials and Biostatistics, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Laboratory and Oncology, Mayo Clinic, Rochester, MN, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN,
Abstract
Safety of concurrent use of radiotherapy for second primary malignancy (SPM) in patients with chronic lymphocytic leukemia (CLL) receiving novel agent therapy.Org: Mayo Clinic, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Division of Clinical Trials and Biostatistics,
Abstract
Cardiovascular adverse events associated with second generation Bruton tyrosine kinase inhibitor therapy: A systematic review and meta-analysis.Org: Mount Sinai Hospital, University of Louisville, UPMC Harrisburg,
Abstract
Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US).Org: Moffitt Cancer Center, Tampa, FL, BeiGene USA, Inc., San Mateo, CA, San Mateo, CA, Formerly with BeiGene USA, Inc.,
Product
acalabrutinibProduct
Calquence